Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib
BackgroundSelpercatinib, a selective RET kinase inhibitor, is approved for treating various cancers with RET gene mutations such as RET-rearranged thyroid cancer and non-small cell lung cancer. The presence of process-related and degradation impurities in its active pharmaceutical ingredient (API) c...
Saved in:
Main Authors: | Jingjing Xiang, Liangliang Cai, Qin Wang, Yonghong Zhu, Yong Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Chemistry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2024.1534132/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01) -
Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
by: Raffaella Pagliaro, et al.
Published: (2025-01-01) -
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Degradation Kinetics of Ascorbic Acid in Xanthan Gum Solution
by: Runqi JIA, et al.
Published: (2025-02-01) -
Innovative determination of phytohormones in Aloe vera
by: Muhammad K. Hakeem, et al.
Published: (2025-01-01)